Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial

Systems Level Analysis of Systemic Sclerosis Shows a Network of Immune and Profibrotic Pathways Connected with Genetic Polymorphisms

(2015) J. Matthew Mahoney et al.   PLoS Computational Biology

Experimentally-Derived Fibroblast Gene Signatures Identify Molecular Pathways Associated with Distinct Subsets of Systemic Sclerosis Patients in Three Independent Cohorts

(2015) Michael E. Johnson et al.   PLoS One

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

(2014) Luca Richeldi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Correction: Molecular Subsets in the Gene Expression Signatures of Scleroderma Skin

(2014) Ausra Milano et al.   PLoS One

Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study

(2014) Paolo Fraticelli et al.   ARTHRITIS RESEARCH & THERAPY

Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors

(2013) Britta Maurer et al.   ANNALS OF THE RHEUMATIC DISEASES

Molecular Signatures in Skin Associated with Clinical Improvement during Mycophenolate Treatment in Systemic Sclerosis

(2013) Monique Hinchcliff et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Cardiac arrhythmias and conduction defects in systemic sclerosis

(2013) Alessandra Vacca et al.   RHEUMATOLOGY

Patterns and predictors of change in outcome measures in clinical trials in scleroderma: An individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis

(2012) P. A. Merkel et al.   ARTHRITIS AND RHEUMATISM

Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial

(2012) S. Prey et al.   BRITISH JOURNAL OF DERMATOLOGY

Nilotinib-Associated Vascular Events

(2012) Alfonso Quintás-Cardama et al.   Clinical Lymphoma Myeloma & Leukemia

Intrinsic Gene Expression Subsets of Diffuse Cutaneous Systemic Sclerosis Are Stable in Serial Skin Biopsies

(2012) Sarah A. Pendergrass et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML

(2011) Karl J. Aichberger et al.   AMERICAN JOURNAL OF HEMATOLOGY

Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial

(2011) R. F. Spiera et al.   ANNALS OF THE RHEUMATIC DISEASES

A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease

(2011) Dinesh Khanna et al.   ARTHRITIS AND RHEUMATISM

Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center

(2011) Janet Pope et al.   ARTHRITIS AND RHEUMATISM

Evidence-based management of rapidly progressing systemic sclerosis

(2010) Dinesh Khanna et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

(2010) H. M. Kantarjian et al.   BLOOD

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: Analysis of three large multicenter, double-blind, randomized controlled trials

(2009) Sogol Amjadi et al.   ARTHRITIS AND RHEUMATISM

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

(2009) Paul W. Manley et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

A TGFβ-Responsive Gene Signature Is Associated with a Subset of Diffuse Scleroderma with Increased Disease Severity

(2009) Jennifer L. Sargent et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

(2009) David A. Barbie et al.   NATURE

Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis

(2008) Alfiya Akhmetshina et al.   FASEB JOURNAL

Role of PDGF in fibrotic diseases and systemic sclerosis

(2008) M. Trojanowska   RHEUMATOLOGY